{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:37:55Z","timestamp":1768419475136,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2018.00315","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T05:12:26Z","timestamp":1541740346000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Pemphigus Foliaceus\u2014Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report"],"prefix":"10.3389","volume":"5","author":[{"given":"Magdalena","family":"Kraft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1084\/jem.160.5.1509","article-title":"Human autoantibodies against a desmosomal core protein in pemphigus foliaceus","volume":"160","author":"Koulu","year":"1984","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1172\/JCI5252","article-title":"Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris","volume":"103","author":"Mahoney","year":"1999","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/ddg.12606","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Eming","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/bjd.13586","article-title":"Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature","volume":"172","author":"de Sena Nogueira Maehara","year":"2015","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/bjd.13307","article-title":"Rituximab in patients with recalcitrant autoimmune blistering diseases: experience in a cohort of 22 patients","volume":"172","author":"Tomsitz","year":"2015","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.1252","article-title":"Rituximab treatment of pemphigus foliaceus - a retrospective study of 12 patients","author":"Palacios-\u00c1lvarez","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low dose rituximab is effective in pemphigus","volume":"166","author":"Horvath","year":"2012","journal-title":"Br J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00810","article-title":"Ultra-low dosage regimen of rituximab in autoimmune blistering skin conditions","author":"Alaibac","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41598-017-17934-6","article-title":"Single, very low rituximab doses in healthy volunteers \u2013 a pilot and a randomized trial: implications for dosing and biosimilarity testing","volume":"8","author":"Schoergenhofer","year":"2018","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/1346-8138.13757","article-title":"Adjuvant rituximab treatment for pemphigus: a retrospective study of 45 patients at a single center with long-term follow up","volume":"44","author":"Kim","year":"2017","journal-title":"J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000357031","article-title":"Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial","volume":"228","author":"Gregoriou","year":"2014","journal-title":"Dermatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaad.2018.01.029","article-title":"A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab","volume":"79","author":"Saleh","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1510173","article-title":"Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients","author":"Keeley","year":"2018","journal-title":"J Dermatolog Treat."},{"key":"B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2018.00315\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T05:12:27Z","timestamp":1541740347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2018.00315\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":24,"alternative-id":["10.3389\/fmed.2018.00315"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2018.00315","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"article-number":"315"}}